Toshihiro Kumabe
A5089034435- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Brain Metastases and Treatment
- Vascular Malformations Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- Advanced Neuroimaging Techniques and Applications
- Testicular diseases and treatments
- Intracranial Aneurysms: Treatment and Complications
- Neuroblastoma Research and Treatments
- Advanced MRI Techniques and Applications
- Neurofibromatosis and Schwannoma Cases
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Chromatin Remodeling and Cancer
- Cerebrovascular and Carotid Artery Diseases
- Hedgehog Signaling Pathway Studies
- Moyamoya disease diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Pituitary Gland Disorders and Treatments
- RNA modifications and cancer
- Intracerebral and Subarachnoid Hemorrhage Research
- MRI in cancer diagnosis
- Ocular Oncology and Treatments
- Acute Ischemic Stroke Management
Kitasato University
2016-2025
Tohoku University
2014-2023
Kitasato University Hospital
2015-2023
Nagoya University
2023
Kyoto University
2016-2019
Tokyo National Hospital
2019
Tokyo Women's Medical University
2013-2018
Miyazaki Prefectural Hospital
2018
Nihon University
2018
Yamagata University
2016-2018
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight need molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify full spectrum of driver genes molecular processes that operate in medulloblastoma subgroups. Here we analyse somatic landscape across 491 sequenced samples heterogeneity among 1,256 epigenetically analysed cases, subgroup-specific...
Medulloblastoma, the most common malignant paediatric brain tumour, is currently treated with nonspecific cytotoxic therapies including surgery, whole-brain radiation, and aggressive chemotherapy. As medulloblastoma exhibits marked intertumoural heterogeneity, at least four distinct molecular variants, previous attempts to identify targets for therapy have been underpowered because of small samples sizes. Here we report somatic copy number aberrations (SCNAs) in 1,087 unique...
Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through inclusion molecular subgroup profiles.We determined affiliation, mutation status, and clinical outcome a discovery cohort 397 medulloblastomas. subsequently validated our results on an independent 156 medulloblastomas.TP53 are enriched wingless (WNT; 16%) sonic hedgehog (SHH; 21%) medulloblastomas virtually absent subgroups 3 4 tumors (P < .001). Patients...
To retrospectively assess the apparent diffusion coefficient (ADC) for prediction of malignancy and prognosis malignant astrocytic tumors.The institutional review board approved this study did not require patient informed consent. Findings from 37 consecutive patients (21 men, 16 women; mean age, 43 years) with pathologically proved tumors that included 22 glioblastomas (GBMs) 15 anaplastic astrocytomas (AAs) were evaluated. The minimum ADC value each tumor was preoperatively determined...
Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, histologic variant. Stark prognostic genetic differences among the subgroups suggest that subgroup-specific biomarkers could improve prognostication.Molecular were identified from a discovery set 673 medulloblastomas 43 cities around world. Combined risk stratification models...
Purpose Whereas whole-brain radiotherapy (WBRT) has been the standard treatment of brain metastases (BMs), stereotactic radiosurgery (SRS) is increasingly preferred to avoid cognitive dysfunction; however, it not clearly determined whether with SRS as effective that WBRT or plus SRS. We thus assessed noninferiority salvage in patients BMs. Patients and Methods age 20 79 years old performance status scores 0 2-and 3 if caused only by neurologic deficits-and four fewer surgically resected BMs...
A recent study reported on mutations in the active site of isocitrate dehydrogenase 1 ( IDH1 ) gene several types gliomas. All detected resulted an amino acid exchange at position 132. We analyzed genomic region spanning wild‐type R132 by direct sequencing 125 glial tumors. total 39 were observed. Mutations IDH2 gene, homologous to , often gliomas without mutations. In present study, R172 mutation was one anaplastic astrocytoma. or frequently oligodendrogliomas (67%), astrocytomas (62%),...
Abstract Sonic hedgehog medulloblastoma encompasses a clinically and molecularly diverse group of cancers the developing central nervous system. Here, we use unbiased sequencing transcriptome across large cohort 250 tumors to reveal differences among molecular subtypes disease, demonstrate previously unappreciated importance non-coding RNA transcripts. We identify alterations within cAMP dependent pathway ( GNAS , PRKAR1A ) which converge on GLI2 activity show that 18% have genetic event...
Abstract Background Approximately 70% of lower-grade gliomas harbor isocitrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation oncometabolite D-2-hydroxyglutarate (D-2-HG); this leads to epigenetic dysregulation, oncogenesis, and subsequent clonal expansion. DS-1001 is an oral brain-penetrant mutant IDH1 selective inhibitor. This first-in-human study investigated safety, pharmacokinetics, pharmacodynamics, efficacy DS-1001. Methods was a multicenter, open-label,...
Long-term outcomes are unknown in patients with asymptomatic moyamoya disease. In this report, we aimed to clarify their 5-year risk of stroke and its predictors.We conducting a multicenter, prospective cohort study (Asymptomatic Moyamoya Registry) Japan. Participants were eligible if they 20 70 years, had bilateral or unilateral disease, experienced no episodes suggestive TIA stroke; functionally independent (modified Rankin Scale score 0-1). Demographic radiological information was...
We conducted a phase III trial of personalized peptide vaccination (PPV) for human leukocyte antigen (HLA)-A24+ recurrent glioblastoma to develop new treatment modality.We randomly assigned 88 patients receive PPV (n = 58) or the placebo 30) at 2-to-1 ratio. Four 12 warehouse peptides selected based on preexisting peptide-specific immunoglobulin G levels corresponding placebos were injected 1×/week weeks.Our met neither primary (overall survival [OS]) nor secondary endpoints. Unfavorable...
Primary CNS germ cell tumors (GCTs) are rare neoplasms predominantly observed in the pediatric and young adult populations. In line with hypothesis that primordial is cell-of-origin, histopathological examinations for this pathology involve a diverse range of components mirroring embryogenic developmental dimensions. Chemotherapy radiotherapy mainstays treatment, surgery having limited role diagnosis debulking residual tissue after treatment. While better management has been achieved over...